Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer

JL Mohler, MA Titus, S Bai, BJ Kennerley, FB Lih… - Cancer research, 2011 - AACR
The androgen receptor (AR) mediates the growth of benign and malignant prostate in
response to dihydrotestosterone (DHT). In patients undergoing androgen deprivation …
被引用次数：192 相关文章

Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.

JL Mohler, MA Titus, S Bai, BJ Kennerley, FB Lih… - Cancer …, 2011 - europepmc.org
The androgen receptor (AR) mediates the growth of benign and malignant prostate in
response to dihydrotestosterone (DHT). In patients undergoing androgen deprivation …

Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer

JL Mohler, MA Titus, S Bai, BJ Kennerley, FB Lih… - Cancer …, 2011 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The androgen receptor (AR) mediates the
growth of benign and malignant prostate in response to dihydrotestosterone (DHT). In …
[PDF] archive.org

[PDF][PDF] Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer

JL Mohler, MA Titus, S Bai, BJ Kennerley, FB Lih… - Cancer Res, 2011 - scholar.archive.org
The androgen receptor (AR) mediates the growth of benign and malignant prostate in
response to dihydrotestosterone (DHT). In patients undergoing androgen deprivation …
[PDF] researchgate.net

[PDF][PDF] Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer

JL Mohler, MA Titus, S Bai, BJ Kennerley, FB Lih… - Cancer Res, 2011 - researchgate.net
The androgen receptor (AR) mediates the growth of benign and malignant prostate in
response to dihydrotestosterone (DHT). In patients undergoing androgen deprivation …

Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer

JL Mohler, MA Titus, S Bai, BJ Kennerley, FB Lih… - Cancer …, 2011 - cdr.lib.unc.edu
The androgen receptor (AR) mediates the growth of benign and malignant prostate in
response to dihydrotestosterone (DHT). In patients undergoing androgen deprivation …

[引用][C] Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer

JL MOHLER, MA TITUS, S BAI… - Cancer research …, 2011 - pascal-francis.inist.fr
Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to
Dihydrotestosterone in Prostate Cancer CNRS Inist Pascal-Francis CNRS Pascal and …
[HTML] nih.gov

[HTML][HTML] Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer

JL Mohler, MA Titus, S Bai, BJ Kennerley, FB Lih… - Cancer …, 2011 - ncbi.nlm.nih.gov
The androgen receptor (AR) mediates the growth of benign and malignant prostate in
response to dihydrotestosterone (DHT). In patients undergoing androgen deprivation …

Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer

JL Mohler, MA Titus, S Bai, BJ Kennerley… - Cancer …, 2011 - pubmed.ncbi.nlm.nih.gov
The androgen receptor (AR) mediates the growth of benign and malignant prostate in
response to dihydrotestosterone (DHT). In patients undergoing androgen deprivation …

Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer

JL Mohler, MA Titus, S Bai… - Cancer …, 2011 - mdanderson.elsevierpure.com
The androgen receptor (AR) mediates the growth of benign and malignant prostate in
response to dihydrotestosterone (DHT). In patients undergoing androgen deprivation …